Biofrontera (BFRI)
Provides AMELUZ and RhodoLED photodynamic therapy for dermatology practices.
Something off on this page? Send us feedback.
Sells AMELUZ prescription gel and BF-RhodoLED lamps to U.S. dermatology practices for photodynamic treatment of actinic keratosis. Revenue centers on recurring gel sales supported by installed lamps, while its opportunity depends on product adoption, reimbursement and FDA-approved label expansion.
Commercializes the AMELUZ prescription gel with BF-RhodoLED and RhodoLED XL red-light lamps for photodynamic treatment of actinic keratosis in U.S. dermatology practices. Sales combine recurring gel purchases with lamp placements, supported by a direct field-sales organization, inside sales, medical education and office-level physician training.
Owns the U.S. regulatory dossier, patents, manufacturing rights and contracts for the AMELUZ/RhodoLED platform, acquired from its former German parent. The company is pursuing label expansions beyond face-and-scalp AK, while supply, reimbursement and clinical adoption remain central commercial dependencies. Products continue to be imported from Europe as manufacturing approvals and licenses are sought.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.7M · Total debt $7.5M · Total assets $24.1M · Shareholders' equity $6.0M
- Revenue
- $12.0M
- Operating income
- −$524.0K
- Net income
- −$604.0K
No dividends on record.
| Institutions12 holders · as of Mar 31, 2026 | 18.68% | 2.39M shares | |
| Insiders7 holders · as of Jul 29, 2026 | 20.45% | 2.62M shares | |
| Strategic holders1 holder · as of Jul 9, 2025 | 3.12% | 400.0K shares | |
| Otherremainder | 57.75% | 7.39M shares |
12.80M company shares as of Aug 24, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (14.85M in the company's Sep 3, 2026 report, 12.80M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Rosalind Advisors, Inc.Institution | 9.09% | 1.16M | 13Fas of Mar 31, 2026 |
Aigh Capital Management LLCInstitution | 7.15% | 915,210 | 13Fas of Mar 31, 2026 |
Balaton Aktiengesellschaft DeutscheInsider10 percent owner | 3.58% | 458,884 | Form 4filed Sep 26, 2025 ↗ |
Biofrontera AGStrategicdirector | 3.12% | 400,000 | Form 4filed Jul 9, 2025 ↗ |
Unternehmensberatung Aktiengesellschaft DelphiInsider10 percent owner | 3.12% | 400,000 | Form 4filed Sep 30, 2025 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2025 | Biofrontera AG | director, 10 percent owner: | +3,019 | $0.0006 |
- Bausch Health
Topical 5-FU and imiquimod alternatives contest AK treatment demand.
- Almonty Industries
Tirbanibulin topical therapy competes for actinic-keratosis field treatment.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Biofrontera | $1.51 | −0.33% | $19.5M | — | — | 0.4 | +32.9% |
| Bausch Health | $6.82 | −0.07% | $2.55B | — | 1.5 | 0.2 | +11.2% |
| Almonty Industries | $17.70 | +0.06% | $5.02B | 104.1 | 19.0 | 88.0 | +484.5% |
| Median | 104.1 | 10.2 | 44.1 | +247.9% |